Biogen, Eisai say lecanemab has aced phase 3 Alzheimer's stu...
Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically si